Therapeutic restoration of Wnt7a signaling in NSCLC could be achieved with agents that are already in clinical use, including demethylating agents and the prostacyclin analog Iloprost, which we recently identified as an activator of the Wnt7a signaling pathway [27]. Here, WNT7A is linked to non-small cell lung carcinoma.